Multiple Myeloma – VJHemOnc
In association with our world-leading Editorial Board, VJHemOnc bring you the latest updates in multiple myeloma, directly from the experts.
In association with our world-leading Editorial Board, VJHemOnc bring you the latest updates in multiple myeloma, directly from the experts.
All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.
The OncoAlert Newsletter is now out for June 23-29, 2023
ASTRO and BCRF congratulates the recipients of the inaugural ASTRO-BCRF Medical Student Fellowship Mentor Awards.
View a list of past and present Minority Summer Fellowship awardees.
Major Finding:Â Anti-TRBC1 chimeric antigen receptor T-cell activity is limited by fratricide by normal TRBC1+ T cells. Concept:Â Development of an anti-TRBC1 antibody drug conjugate (ADC) demonstrates…
Researchers have investigated whether adjuvant radiation therapy may improve the function of artificial urinary sphincters for stress urinary incontinence in patients who have undergone surgery…
Financial toxicity is an increasing problem for patients with gynecologic cancer. Our analysis, using objective measures of financial toxicity, has suggested that demographic factors and…
HRR testing is underused in patients with metastatic castration-resistant prostate cancer, a large study suggests.
Researchers sought to measure the knowledge and understanding of genetic and genomic testing and their influence on treatment decisions and options.
Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether…